Cargando…

Chronic myeloid leukemia stem cells

Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC). In humans a CML LSC is operationally-defined by ≥1 in vitro or in vivo assays of human leukemia cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houshmand, Mohammad, Simonetti, Giorgia, Circosta, Paola, Gaidano, Valentina, Cignetti, Alessandro, Martinelli, Giovanni, Saglio, Giuseppe, Gale, Robert Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755964/ https://www.ncbi.nlm.nih.gov/pubmed/31127148 http://dx.doi.org/10.1038/s41375-019-0490-0

Ejemplares similares

Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells
por: Houshmand, Mohammad, et al.
Publicado: (2021)

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia
por: Gaidano, Valentina, et al.
Publicado: (2021)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
por: Houshmand, Mohammad, et al.
Publicado: (2021)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2022)

Bone marrow microenvironment: The guardian of leukemia stem cells
por: Houshmand, Mohammad, et al.
Publicado: (2019)

Nanocarriers as Magic Bullets in the Treatment of Leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2020)

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety
por: Sainas, Stefano, et al.
Publicado: (2021)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia
por: Marconi, Caterina, et al.
Publicado: (2017)

A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning
por: Gaidano, Valentina, et al.
Publicado: (2020)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Atypical Chronic Myeloid Leukemia: Where Are We Now?
por: Crisà, Elena, et al.
Publicado: (2020)

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
por: Li, Bing, et al.
Publicado: (2014)

A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia
por: Bernardoni, Roberto, et al.
Publicado: (2019)

Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
por: Simonetti, Giorgia, et al.
Publicado: (2021)

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase
por: Crivellaro, Sabrina, et al.
Publicado: (2016)

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety
por: Sainas, Stefano, et al.
Publicado: (2022)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Will immune therapy cure acute myeloid leukemia?
por: Gale, Robert Peter
Publicado: (2019)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Leukemia stem cells: the root of chronic myeloid leukemia
por: Zhou, Hong, et al.
Publicado: (2015)

Can Immune Therapy Cure Acute Myeloid Leukemia?
por: Gale, Robert Peter
Publicado: (2023)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups
por: Riva, L, et al.
Publicado: (2014)

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups
por: Riva, L, et al.
Publicado: (2013)

Chronic Myeloid Leukemia Stem Cell Biology
por: Crews, Leslie A., et al.
Publicado: (2012)

Stem Cell Biomarkers in Chronic Myeloid Leukemia
por: Jiang, Xiaoyan, et al.
Publicado: (2008)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells
por: Salvestrini, Valentina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4t1au1j9etdtfbqiareifhqc2s